Blood
Articles in this Issue
Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic leukemia/small lymphocytic lymphoma
Sickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review
Abstract Globally, an estimated 300 million individuals have sickle cell trait (SCT), the carrier state for sickle cell disease (SCD). Although SCD is associated with increased morbi...
Targeting an AML-sustaining metabolic node
Atypical chronic myeloid leukemia: from cytology to molecular characterization
Taming JAK cytokine release in haplo-transplant
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Abstract Excessively restrictive inclusion and exclusion criteria in clinical trials are one of many barriers to clinical trial enrollment for patients with myelodysplastic syndromes...
Two-layered immune escape in AML is overcome by Fcγ receptor activation and inhibition of PGE2 signaling in NK cells
Abstract Loss of anticancer natural killer (NK) cell function in patients with acute myeloid leukemia (AML) is associated with fatal disease progression and remains poorly understood...
Jumping barriers in clinical trials: release the brake
Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation
Abstract Haploidentical hematopoietic cell transplantation (haplo-HCT) is an increasingly used treatment for hematologic malignancies. Although posttransplant cyclophosphamide (PtCy)...
Two is better than one: dual targeting of WDR5 in T-ALL
Impact of new medications on the treatment of immune TTP
Abstract The last decade has seen the introduction of 2 new licensed therapies for thrombotic thrombocytopenic purpura (TTP), caplacizumab and recombinant ADAMTS13 (rADAMTS13), for i...
How I diagnose and treat acute infection–associated purpura fulminans
Abstract Purpura fulminans (PF) is a rare but devastating complication of sepsis characterized by a highly thrombotic subtype of disseminated intravascular coagulation (DIC). A medic...
PGE2 inhibition to prevent AML escape from NK cells
Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL
Abstract T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a poor prognosis and limited options for targeted therapies. Identifying new molec...
α-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia
Abstract Perturbations in intermediary metabolism contribute to the pathogenesis of acute myeloid leukemia (AML) and can produce therapeutically actionable dependencies. Here, we p...